tradingkey.logo

Merck Says Keytruda® Plus Trodelvy® Reduced Risk Of Disease Progression Or Death By 35% Versus Keytruda Plus Chemotherapy In First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer

ReutersMay 31, 2025 12:05 PM

- Merck MRK.N:

  • KEYTRUDA® (PEMBROLIZUMAB) PLUS TRODELVY® (SACITUZUMAB GOVITECAN-HZIY) REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 35% VERSUS KEYTRUDA PLUS CHEMOTHERAPY IN FIRST-LINE PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)

  • MERCK & CO INC - KEYTRUDA PLUS TRODELVY SHOWS 11.2 MONTHS MEDIAN PFS VERSUS 7.8 MONTHS WITH CHEMOTHERAPY

  • MERCK & CO INC - KEYTRUDA PLUS TRODELVY SHOWS 35% REDUCTION IN RISK OF DISEASE PROGRESSION OR DEATH

  • MERCK & CO INC - KEYTRUDA PLUS TRODELVY SHOWS 59.7% ORR VERSUS 53.2% WITH CHEMOTHERAPY

  • MERCK & CO INC - KEYTRUDA PLUS TRODELVY SHOWS 16.5 MONTHS DOR VERSUS 9.2 MONTHS WITH CHEMOTHERAPY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI